Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

11/12/24 9:55:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EWTX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 EDGEWISE THERAPEUTICS INC COMMON STOCK Cusip #28036F105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #28036F105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 651,541 Item 6: 0 Item 7: 653,207 Item 8: 0 Item 9: 653,207 Item 11: 0.696% Item 12: HC Cusip #28036F105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 653,207 Item 8: 0 Item 9: 653,207 Item 11: 0.696% Item 12: IN Item 1(a). Name of Issuer: EDGEWISE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 1715 38TH ST BOULDER, CO 80301 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 28036F105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 653,207 (b) Percent of Class: 0.696% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 653,207 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of EDGEWISE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of EDGEWISE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of EDGEWISE THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $EWTX alert in real time by email

Recent Analyst Ratings for

$EWTX

Date	Price Target	Rating	Analyst
11/22/2024	$45.00	Outperform	Evercore ISI
3/7/2024	$48.00	Overweight	Piper Sandler
5/1/2023		Buy	Truist
8/25/2022	$5.00	Neutral → Sell	Goldman
4/13/2022	$31.00	Outperform	RBC Capital Mkts
2/14/2022	$33.00 → $32.00	Overweight	JP Morgan
1/28/2022	$11.00	Neutral	Goldman
1/6/2022	$30.00 → $33.00	Overweight	JP Morgan

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $EWTX

$EWTX Press Releases

Fastest customizable press release news feed in the world

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

$EWTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

SEC Form SC 13G filed by Edgewise Therapeutics Inc.

$EWTX Market Insights

Live Market Insights

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Edgewise Therapeutics shares are trading higher after JP Morgan maintained an Overweight rating and raised the price target from $27 to $30.

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $30

$EWTX SEC Filings

SEC Form S-8 filed by Edgewise Therapeutics Inc.

SEC Form 10-Q filed by Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$EWTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$EWTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Thompson Peter A. bought $4,999,995 worth of shares (454,545 units at $11.00) (SEC Form 4)

Orbimed Advisors Llc bought $4,999,995 worth of shares (454,545 units at $11.00) (SEC Form 4)

Fox Jonathan C bought $100,958 worth of shares (10,857 units at $9.30) (SEC Form 4)

Chief Financial Officer Carruthers R Michael exercised 70,000 shares at a strike of $0.71, increasing direct ownership by 1,014% to 76,904 units (SEC Form 4)

Chief Scientific Officer Russell Alan J exercised 75,000 shares at a strike of $0.18 and sold $2,120,101 worth of shares (75,000 units at $28.27) (SEC Form 4)

General Counsel Moore John R exercised 70,922 shares at a strike of $0.71 and sold $1,996,574 worth of shares (70,922 units at $28.15) (SEC Form 4)

$EWTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Evercore ISI initiated coverage on Edgewise Therapeutics with a new price target

Piper Sandler initiated coverage on Edgewise Therapeutics with a new price target

Truist initiated coverage on Edgewise Therapeutics

$EWTX Leadership Updates

Live Leadership Updates

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

$EWTX Financials

Live finance-specific insights

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

Recent Analyst Ratings for
$EWTX

$EWTX
Press Releases

$EWTX
Large Ownership Changes

$EWTX
Market Insights

$EWTX
SEC Filings

$EWTX
Insider Purchases

$EWTX
Insider Trading

$EWTX
Analyst Ratings

$EWTX
Leadership Updates

$EWTX
Financials